A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
Completed · Phase 2
Conditions studied: Kidney Neoplasms
In brief
The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.
Key facts
- Study ID
- NCT00226980
- Run by
- Stanford University
- People needed
- 30
- Starts
- 2002-10-01
- Expected to finish
- 2006-07-01
- Last updated by the study team
- 2009-04-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.